some our DEFINITY procedures. echo proposed CMS XXXX with the programs. I published XXXX XXth, On with consistent rules Andrea. XXXX you, Thank its July for contrast-enhanced performance updates current will including The now for reimbursement half rates on proposed provide are business for strategic and procedures rates.
XXXX echo to procedures the recognize expected are pattern The DEFINITY. when these have to rules published November. offers pleased CMS incremental rates for needed. in contrast proposed Strategically, state final our are to half added We we that in be value
we our the that XXXX. will U.S. needs. another alternative U.S. that In meets that their flexibility already of facets XXXX portfolio DEFINITY, of choosing to addition the patent will a of for in recently believe the additional addition matter to through offer the of coves composition DEFINITY patient's formulation granted our DEFINITY customers’ in through patterns We formulation run best certain were formulation
and and year. in application key China milestone the to of our was DEFINITY China Next with needed which pharmacokinetics in another we all the this submitted studies, we cardiac, expect the includes completed by liver approval is for enrollment Analysis of reached end Recently FDA resulting for Double-Crane. progress to the kidney, data studies. program be
we shared DEFINITY. pursuing a or Left As LVEF, previously, indication for Fraction, Ejection are Ventricular
LVEF We SPA, for continue assessment, a to work with the on trial special FDA our design. protocol or
initiate are on of trial with is an that exclusivity CRO the sites we new of would addressable be completed, double indication. would echo the If the approximately qualification to which in have activities FDA. laboratory including and we the XXXX started conducting is approved, site have FDA we by with believe of end the marketing three We population fact the could trial remain for and DEFINITY and years used track routine both at core the and stage questions visits. trial not While identifying LVEF in contracting answering patient
capabilities manufacturing help as our Billerica microbubble Additionally, sold campus and to the reliable of on at ensure in-house build our out the cost online, Once improve margin. as gross will remains facility of our schedule. goods supply well
GE patient pipeline, the week, with market. agent This MPI the up payments, III the for and product the multicenter participants in the enrolled GE jointly sales is PET newest and clinical double-digit to trial Healthcare regulatory we earlier co-promote patient agreement in This this our Regarding outside sales sales collaboration announced milestone U.S. collaboration to will open-label economics international of June. projected last agent perspective the occur second Flurpiridaz U.S. this start enroll PET option Phase and future XXX the the royalties F The our with provides license XX with trial in the of first to our Healthcare. August of follow focus with for on of royalties XXXX. single-digit up for and
is and III for first-in-class XXXX believe program. death. cardiac our up Next Fluorine-XX for is we of represents useful a XXXX PET a at Phase risk that population a agent diagnostic based patients tool sudden LMI
needs. on strategy, now our with we address will complement clinical capabilities single have trial market both anticipate planned assessing the external the will and pronged third opportunities. we or growth Ideal the trial. work FDA in unmet an opportunities we SPA undertaken are we current Addressing XXXX, Phase patient for III current While initiate the actively
In or in progress are pleased that now improving to flow. while would coming programs and profit our take questions. accretive and would we you with assets that your are margins ready With to quarters. revenue look prioritize soon addition, Operator? to we closing, I and we updating our be In to the strategic Andrea and on results business forward cash are date
